Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.

The milestone is being celebrated as a “huge moment” for rare disease drug development.

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

Recovery Bay Center expands men’s detox and residential addiction treatment services in Panama City, Florida. We treat the whole person, not just addiction, so men leave here equipped with the tools ...

A year after the Trump Administration designated six Mexican cartels as foreign terrorist organizations, the compliance ...

President Donald Trump has said that Americans are now paying or will pay "the lowest price anywhere in the world for drugs," thanks to the administration’s negotiations with pharmaceutical companies.

However, the NSAC took particular exception with Jaynes as the drug test failure was the third for him in their jurisdiction.

Sound policy is best developed through legislation because it requires group decisions. Prior executive actions to rein in drug prices by this president and his predecessors have not fared well.

FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” ...

Sentante announced that its Sentante stroke system has been accepted into the FDA Total Product Life Cycle Advisory Program (T ...